➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Colorcon
Express Scripts
Johnson and Johnson
AstraZeneca

Last Updated: August 2, 2021

DrugPatentWatch Database Preview

Ramipril - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic sources for ramipril and what is the scope of patent protection?

Ramipril is the generic ingredient in two branded drugs marketed by King Pharms Llc, Accord Hlthcare, Actavis Elizabeth, Apotex, Aurobindo Pharma Ltd, Chartwell Molecular, Cipla, Dr Reddys Labs Ltd, Hikma, Lupin, Ranbaxy Labs Ltd, Teva Pharms, Watson Labs, Yaopharma Co Ltd, Zydus Pharms Usa, King Pfizer, Mylan Pharms Inc, and Zydus Pharms Usa Inc, and is included in nineteen NDAs. Additional information is available in the individual branded drug profile pages.

There are nineteen drug master file entries for ramipril. Twenty-two suppliers are listed for this compound.

Drug Prices for ramipril

See drug prices for ramipril

Drug Sales Revenue Trends for ramipril

See drug sales revenues for ramipril

Recent Clinical Trials for ramipril

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of BariPhase 4
Fondazione SchenaPhase 4
PfizerPhase 2

See all ramipril clinical trials

Pharmacology for ramipril
Medical Subject Heading (MeSH) Categories for ramipril
Paragraph IV (Patent) Challenges for RAMIPRIL
Tradename Dosage Ingredient NDA Submissiondate
ALTACE CAPSULE;ORAL ramipril 019901

US Patents and Regulatory Information for ramipril

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms Usa RAMIPRIL ramipril CAPSULE;ORAL 078832-002 Sep 2, 2008 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-002 Jan 28, 1991 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-002 Feb 27, 2007 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ramipril

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pfizer ALTACE ramipril TABLET;ORAL 022021-001 Feb 27, 2007 ⤷  Free Forever Trial ⤷  Free Forever Trial
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-002 Jan 28, 1991 ⤷  Free Forever Trial ⤷  Free Forever Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-003 Feb 27, 2007 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Colorcon
Express Scripts
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.